Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1649376 | 0.88 | POLB (0.66) | LMNAKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL1647843 | 0.87 | KDM4E (0.62) | LMNAKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL1000486 | 0.83 | POLB (0.74) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL6499156 | 0.83 | POLB (0.51) | LMNAKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL1546612 | 0.81 | POLB (0.76) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL21681933 | 0.81 | ALDH1A1 (0.62) | GLALMNAKDM4EALDH1A1HPGD | |
| SCHEMBL17363910 | 0.79 | HSD17B10 (0.62) | LMNAKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL9436741 | 0.79 | GLA (1.00) | GLALMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL4469033 | 0.78 | SERPINE1 (0.72) | LMNAKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL1546948 | 0.77 | ALDH1A1 (0.64) | GLALMNAKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483254-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2014-08-13 | — | — | EP | disclosed |
| US-8778939-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| EP-2483254-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184553-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-19 | — | — | US | disclosed |
| WO-2011038572-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184553-A1 | NOVEL COMPOUNDS | LRRK2, PARK7, PINK1 | GLA 1135/4885LMNA 2250/4885KDM4E 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.